![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
HO Heuer, J Casals-Stenzel, G Muacevic and KH Weber
Department of Pharmacology, Boehringer Ingelheim KG, Ingelhelm/Rh., Germany.
The hetrazepine WEB 2170 (international nonproprietary name: bepafant), a thieno-triazolodiazepine that is structurally related to the recently described platelet activating factor (PAF) antagonist WEB 2086, is a potent and selective PAF antagonist both in vitro and in vivo. WEB 2170 inhibited PAF-induced human platelet and neutrophil aggregation in vitro (IC50 values: 0.3 and 0.83 microM, respectively) but had little or no inhibitory action against aggregation induced by other agonists. The potency in vitro was comparable to that described recently for WEB 2086 (Casals-Stenzel, J., Muacevic, G. and Weber, K.H.: J. Pharmacol. Exp. Ther. 241: 974-981, 1987). When guinea pigs were given i.v. infusions of PAF at 30 ng x kg-1 x min-1, oral (0.005-0.5 mg/kg) as well as intravenous (0.005-0.05 mg/kg) treatment with WEB 2170 abrogated the intrathoracic accumulation of 111In-labeled platelets, the bronchoconstriction and the hypotension as well as the finally occurring death in a dose-dependent fashion. Oral (0.01-1 mg/kg) and intravenous (0.005-0.1 mg/kg) WEB 2170 shared with the beta 2 agonist fenoterol and the steroid dexamethasone the property of protecting elderly NMRI mice from the lethal effect of PAF. In anesthetized rats, intravenous (0.001-0.1 mg/kg) and oral (0.05-1 mg/kg) WEB 2170 inhibited PAF-induced hypotension in a dose-related manner. Coadministration of WEB 2170 inhibited PAF-induced increase of vascular permeability in rat skin very effectively. The half-time of duration of action in the rat was estimated to be about 5 to 6 h after oral administration and about 1.1 to 2.3 h after intravenous application. In conclusion, the hetrazepine WEB 2170 is a strong and selective PAF antagonist, which is in vitro more or less equipotent to WEB 2086. In contrast, in vivo oral WEB 2170 is--depending on the species and considered parameter--about 5 to 40 times more potent against exogenous PAF-induced alterations than the recently described hetrazepine WEB 2086. Particularly in mice and rats, oral WEB 2170 is by far superior to WEB 2086.
This article has been cited by other articles:
|
|
 |
|
  W. Zhou, B. O. Ibe, and J. U. Raj Platelet-activating factor induces ovine fetal pulmonary venous smooth muscle cell proliferation: role of epidermal growth factor receptor transactivation Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2773 - H2781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Boccellino, G. Camussi, A. Giovane, L. Ferro, V. Calderaro, C. Balestrieri, and L. Quagliuolo Platelet-Activating Factor Regulates Cadherin-Catenin Adhesion System Expression and {beta}-Catenin Phosphorylation during Kaposi's Sarcoma Cell Motility Am. J. Pathol., May 1, 2005; 166(5): 1515 - 1522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Penna, G. Alloatti, S. Cappello, D. Gattullo, G. Berta, B. Mognetti, G. Losano, and P. Pagliaro Platelet-activating factor induces cardioprotection in isolated rat heart akin to ischemic preconditioning: role of phosphoinositide 3-kinase and protein kinase C activation Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2512 - H2520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A K Ewer, W Al-Salti, A M Coney, J M Marshall, P Ramani, and I W Booth The role of platelet activating factor in a neonatal piglet model of necrotising enterocolitis Gut, February 1, 2004; 53(2): 207 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Russo, B. Bussolati, I. Deambrosis, F. Mariano, and G. Camussi Platelet-Activating Factor Mediates CD40-Dependent Angiogenesis and Endothelial-Smooth Muscle Cell Interaction J. Immunol., November 15, 2003; 171(10): 5489 - 5497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Silliman, D. J. Elzi, D. R. Ambruso, R. J. Musters, C. Hamiel, R. J. Harbeck, A. J. Paterson, A. J. Bjornsen, T. H. Wyman, M. Kelher, et al. Lysophosphatidylcholines prime the NADPH oxidase and stimulate multiple neutrophil functions through changes in cytosolic calcium J. Leukoc. Biol., April 1, 2003; 73(4): 511 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Silliman, L. K. Boshkov, Z. Mehdizadehkashi, D. J. Elzi, W. O. Dickey, L. Podlosky, G. Clarke, and D. R. Ambruso Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors Blood, January 15, 2003; 101(2): 454 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Arese, C. Ferrandi, L. Primo, G. Camussi, and F. Bussolino HIV-1 Tat Protein Stimulates In Vivo Vascular Permeability and Lymphomononuclear Cell Recruitment J. Immunol., January 15, 2001; 166(2): 1380 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Alloatti, C. Penna, F. Mariano, and G. Camussi Role of NO and PAF in the impairment of skeletal muscle contractility induced by TNF-alpha Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2000; 279(6): R2156 - R2163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bussolati, L. Biancone, P. Cassoni, S. Russo, M. Rola-Pleszczynski, G. Montrucchio, and G. Camussi PAF Produced by Human Breast Cancer Cells Promotes Migration and Proliferation of Tumor Cells and Neo-Angiogenesis Am. J. Pathol., November 1, 2000; 157(5): 1713 - 1725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Cavallo-Perin, E. Lupia, G. Gruden, C. Olivetti, A. De Martino, M. Cassader, D. Furlani, L. Servillo, L. Quagliuolo, E. Iorio, et al. Increased blood levels of platelet-activating factor in insulin-dependent diabetic patients with microalbuminuria Nephrol. Dial. Transplant., July 1, 2000; 15(7): 994 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Montrucchio, E. Lupia, E. Battaglia, L. Del Sorbo, M. Boccellino, L. Biancone, G. Emanuelli, and G. Camussi Platelet-Activating Factor Enhances Vascular Endothelial Growth Factor-Induced Endothelial Cell Motility and Neoangiogenesis in a Murine Matrigel Model Arterioscler. Thromb. Vasc. Biol., January 1, 2000; 20(1): 80 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Biancone, V. Cantaluppi, M. Boccellino, B. Bussolati, L. Del Sorbo, P. G. Conaldi, A. Albini, A. Toniolo, and G. Camussi Motility Induced by Human Immunodeficiency Virus-1 Tat on Kaposi’s Sarcoma Cells Requires Platelet-Activating Factor Synthesis Am. J. Pathol., November 1, 1999; 155(5): 1731 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Dentelli, L. D. Sorbo, A. Rosso, A. Molinar, G. Garbarino, G. Camussi, L. Pegoraro, and M. F. Brizzi Human IL-3 Stimulates Endothelial Cell Motility and Promotes In Vivo New Vessel Formation J. Immunol., August 15, 1999; 163(4): 2151 - 2159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Brizzi, E. Battaglia, G. Montrucchio, P. Dentelli, L. Del Sorbo, G. Garbarino, L. Pegoraro, and G. Camussi Thrombopoietin Stimulates Endothelial Cell Motility and Neoangiogenesis by a Platelet-Activating Factor–Dependent Mechanism Circ. Res., April 16, 1999; 84(7): 785 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Uhl, S. Pickelmann, A. Baethmann, and L. Schurer Influence of Platelet-Activating Factor on Cerebral Microcirculation in Rats : Part 1. Systemic Application Stroke, April 1, 1999; 30(4): 873 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Uhl, S. Pickelmann, F. Rohrich, A. Baethmann, L. Schurer, and F. M. Faraci Influence of Platelet-Activating Factor on Cerebral Microcirculation in Rats : Part 2. Local Application • Editorial Comment: Part 2. Local Application Stroke, April 1, 1999; 30(4): 880 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Alloatti, C. Penna, A. De Martino, G. Montrucchio, and G. Camussi Role of nitric oxide and platelet-activating factor in cardiac alterations induced by tumor necrosis factor-{alpha} in the guinea-pig papillary muscle Cardiovasc Res, March 1, 1999; 41(3): 611 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. O. Ibe, S. Hibler, and J. U. Raj Platelet-activating factor modulates pulmonary vasomotor tone in the perinatal lamb J Appl Physiol, September 1, 1998; 85(3): 1079 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bussolati, F. Mariano, A. Cignetti, A. Guarini, V. Cambi, R. Foa, G. Piccoli, and G. Camussi Platelet-Activating Factor Synthesized by IL-12-Stimulated Polymorphonuclear Neutrophils and NK Cells Mediates Chemotaxis J. Immunol., August 1, 1998; 161(3): 1493 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ahmed, S. Dearn, M. Shams, X. F. Li, R. K. Sangha, M. Rola-pleszczynski, and J. Jiang Localization, quantification, and activation of platelet-activating factor receptor in human endometrium during the menstrual cycle: PAF stimulates NO, VEGF, and FAKpp125 FASEB J, July 1, 1998; 12(10): 831 - 843. [Abstract] [Full Text]
|
|
|
|
|
|
G. Bellone, P. Astarita, E. Artusio, S. Silvestri, K. Mareschi, A. Turletti, S. Buttiglieri, G. Emanuelli, and L. Matera Bone Marrow Stroma-Derived Prolactin Is Involved in Basal and Platelet-Activating Factor-Stimulated In Vitro Erythropoiesis Blood, July 1, 1997; 90(1): 21 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Schaloske, C Sordano, S Bozzaro, and D Malchow Stimulation of calcium influx by platelet activating factor in Dictyostelium J. Cell Sci., January 4, 1995; 108(4): 1597 - 1603. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
